SDC1 and neoplasm: GSH treatment protected CD138+ tumor cells from melphalan-induced toxicity in all the patients investigated with a median 2.3 fold increase of the number of CD138+ cells (Figure 4) (p < 0.05, < 0.005 and < 0.005 for 10, 20 and 30 μM of melphalan, respectively).